Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 10OTHER_GOV 2INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 2Prostatic Neoplasms 1Pancreatic cancer, adult 1Ovarian Neoplasms 1Opioid-Related Disorders 1Lymphoma, Follicular 1Lung Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 65Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 30Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Rituximab 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Hematologic Tests × Clear all
NCT06717295 2026-01-02

CCANED-CIPHER

Dysplasia Diagnostics Limited

Recruiting
6,000 enrolled
CNSGastrointestinalGenitourinaryGynecologicThoracic

Pancreatic cancer, adult, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02288754 2019-08-14

Detection of Tumor DNA in Blood Samples From Cancer Patients

Lexent Bio, Inc.

Unknown
500 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡